BioSpace News Archive

Kintara Therapeutics, Inc. announced that three posters have been accepted for data presentation at the 2022 Society for Neuro-Oncology Annual Meeting.

Sequana Medical NV announces its business highlights and financial results for the six-month period ending 30 June 2022 and its outlook for the remainder of the year and beyond.

Basilea Pharmaceutica Ltd. announced that it has entered into an asset purchase agreement with Nodus Oncology for Basilea’s novel poly glycohydrolase inhibitor discovery program.

Sensorion is pleased to announce Sensorion’s participation, in-person, in the Inner Ear Biology Workshop, taking place on September 10-13, 2022, in Trieste, Italy.

LifeArc announced that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, has been acquired by ArcutisBiotherapeutics, Inc., a California-based early commercial stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology.

Teva Pharmaceutical Industries Ltd. announces the results of two studies1,2 presented at the Migraine Trust International Symposium in London, UK, which demonstrate the efficacy of AJOVY▼ in migraine patients who also experience depression or anxiety.

Genus, a leading global animal genetics company, announces its preliminary results for the year ended 30 June 2022.

Cardior Pharmaceuticals announced the CE marking of its PCR kit which measures circulating microRNA-132 levels in the blood of patients receiving the company’s lead candidate CDR132L, an oligonucleotide-based miR-132 inhibitor.

Cardinal Health announced Debbie Weitzman, current President of Pharmaceutical Distribution, will become CEO of the Company’s Pharmaceutical Segment.

Renalytix plc announced the company will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022.